CCRT Followed by PD-1 Inhibitor Maintenance Therapy in Locally Advanced ESCC

The goal of this clinical trial is to learn if concurrent chemoradiotherapy followed by immunotherapy as maintenance therapy works to treat locally advanced esophageal squamous cell cancer in adults.

Trial Details

NCT ID
NCT06964568
Phase
PHASE3
Sponsor
Fudan University
Status
RECRUITING
Cancer Type
Esophageal Cancer
Interventions
  • PD-1 inhibitor
  • Unlimited radiotherapy
  • TP regimen
  • TDLN-sparing radiotherapy
Locations (sample)
  • Shanghai, China|31.22222,121.45806

Key Eligibility Criteria

  • Written informed consent
  • Aged 18 years or above
  • Histologically confirmed esophageal squamous cell carcinoma
  • Clinical stages T3-4N0M0 or TxN+M0 or TxNxM1 (Only for supraclavicular lymph nodes) based on the 8th UICC-TNM classification

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Esophageal Cancer Trials on Trialify →